Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Urine as a true non-invasive sampling source holds great potential for biomarker discovery. While approximately 2000 proteins can be detected by mass spectrometry in urine from healthy people, the amount of these proteins vary considerably. A systematic evaluation of a large number of samples is needed to determine the range of the variations. Current biomarker studies often measure limited number of urine samples in the discovery phase, which makes it difficult to determine whether proteins differentially expressed between control and disease groups represent actual difference, or are just physiological variations among the individuals, leads to failures in the validation phase with the increased sample numbers. Here, we report a streamlined workflow with capacity of measuring 8 urine proteomes per day at the coverage of >1500 proteins. With this workflow, we evaluated variations in 497 urine proteomes from 167 healthy donors, establishing reference intervals (RIs) that covered urine protein variations. We demonstrated that RIs could be used to monitor physiological changes by detecting transient outlier proteins. Furthermore, we provided a RIs-based algorithm for biomarker discovery and validation to screen for diseases such as cancer. This study provided a proof-of-principle workflow for the use of urine proteome for health monitoring and disease screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566 · cited 1×
“For protein quantification, intensity based absolute quantification (iBAQ) algorithm (Schwanhausser et al., 2011) was used.”
MethodDefining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 2×
“One reason for these translational failures was the small sample size included in the studies, which did not have enough statistical power to distinguish between the difference resulting from pathological changes and the physiological variations among different individuals (Rifai et al., 2006; Rodriguez-Suarez et al.,…”
BackgroundReactome: a database of reactions, pathways and biological processes
Croft, D., O'Kelly, G., Wu, G., Haw, R., Gillespie, M., Matthews, L., Caudy, M., Garapati, P., Gopinath, G., Jassal, B., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1018 · Cited by 1,751 · cited 2×
“org) (Croft et al., 2011) revealed that many outliers were enriched in pathways associated with immune response (Fig.”
BackgroundMethodThongboonkerd, V., Mcleish, K. R., Arthur, J. M., & Klein, J. B. (2002) · Kidney International · doi:10.1111/j.1523-1755.2002.kid565.x · Cited by 359 · cited 1×
“Much effort has been made to characterize protein composition of urine using mass spectrometry (MS) during the last decade (Adachi et al., 2006; Kentsis et al., 2009; Khristenko et al., 2016; Marimuthu et al., 2011; Nagaraj and Mann, 2011; Sun et al., 2009; Thongboonkerd et al., 2002).”
BackgroundRubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296 · cited 1×
“IDH2, MTOR and SF3B1 (see Supplementary Table 6) are encoded by cancer driver genes (Rubio-Perez et al., 2015).”
BackgroundUrinary Biomarkers of Brain Diseases
An, M., & Gao, Y. (2015) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.08.005 · Cited by 142
Research works printed but not linked: 42
- Adachi, 2006, The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins, Genome Biol., 7, R80, 10.1186/gb-2006-7-9-r80 · DOI · Paper page
- Anderson, 2010, The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum, Clin. Chem., 56, 177, 10.1373/clinchem.2009.126706 · DOI · Paper page
- Beretov, 2015, Proteomic analysis of urine to identify breast cancer biomarker candidates using a label-free LC-MS/MS approach, PLoS One, 10, 10.1371/journal.pone.0141876 · DOI
- Coon, 2008, CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics, Proteomics Clin. Appl., 2, 964, 10.1002/prca.200800024 · DOI · Paper page
- Court, 2015, Urine sample preparation and fractionation for global proteome profiling by LC-MS, Methods Mol. Biol., 1243, 175, 10.1007/978-1-4939-1872-0_10 · doi:10.1007/978-1-4939-1872-0_10
- Decramer, 2008, Urine in clinical proteomics, Mol. Cell. Proteomics, 7, 1850, 10.1074/mcp.R800001-MCP200 · DOI · Paper page
- Diamond, 2013, The broad-spectrum antiviral functions of IFIT and IFITM proteins, Nat. Rev. Immunol., 13, 46, 10.1038/nri3344 · DOI · Paper page
- Draghici, 2003, Global functional profiling of gene expression, Genomics, 81, 98
- Fuzery, 2013, Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges, Clin. Proteomics, 10, 13, 10.1186/1559-0275-10-13 · DOI · Paper page
- Gao, 2013, Urine-an untapped goldmine for biomarker discovery?, Sci. China Life Sci., 56, 1145, 10.1007/s11427-013-4574-1 · DOI · Paper page
- Goodison, 2009, Urinary proteomic profiling for diagnostic bladder cancer biomarkers, Expert Rev Proteomics, 6, 507, 10.1586/epr.09.70 · DOI
- Haller, 2006, The interferon response circuit: induction and suppression by pathogenic viruses, Virology, 344, 119, 10.1016/j.virol.2005.09.024 · DOI · Paper page
- Hammarstrom, 1999, The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues, Semin. Cancer Biol., 9, 67, 10.1006/scbi.1998.0119 · DOI · Paper page
- Hamosh, 2005, Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders, Nucleic Acids Res., 33, D514, 10.1093/nar/gki033 · DOI · Paper page
- Kentsis, 2009, Urine proteomics for profiling of human disease using high accuracy mass spectrometry, Proteomics Clin. Appl., 3, 1052, 10.1002/prca.200900008 · DOI
- Khristenko, 2016, Longitudinal urinary protein variability in participants of the space flight simulation program, J. Proteome Res., 15, 114, 10.1021/acs.jproteome.5b00594 · DOI
- Lv, 2012, Altered expression levels of IDH2 are involved in the development of colon cancer, Exp. Ther. Med., 4, 801, 10.3892/etm.2012.676 · DOI
- Malovannaya, 2010, Streamlined analysis schema for high-throughput identification of endogenous protein complexes, Proc. Natl. Acad. Sci. U. S. A., 107, 2431, 10.1073/pnas.0912599106 · DOI · Paper page
- Marimuthu, 2011, A comprehensive map of the human urinary proteome, J. Proteome Res., 10, 2734, 10.1021/pr2003038 · DOI · Paper page
- Mischak, 2010, Recommendations for biomarker identification and qualification in clinical proteomics, Sci. Transl. Med., 2, 10.1126/scitranslmed.3001249 · DOI · Paper page
- Nagaraj, 2011, Quantitative analysis of the intra- and inter-individual variability of the normal urinary proteome, J. Proteome Res., 10, 637, 10.1021/pr100835s · DOI · Paper page
- Overbye, 2015, Identification of prostate cancer biomarkers in urinary exosomes, Oncotarget, 6, 30357, 10.18632/oncotarget.4851 · DOI · Paper page
- Pavlou, 2013, The long journey of cancer biomarkers from the bench to the clinic, Clin. Chem., 59, 147, 10.1373/clinchem.2012.184614 · DOI · Paper page
- Pisitkun, 2006, Discovery of urinary biomarkers, Mol. Cell. Proteomics, 5, 1760, 10.1074/mcp.R600004-MCP200 · DOI · Paper page
- Pisitkun, 2004, Identification and proteomic profiling of exosomes in human urine, Proc. Natl. Acad. Sci. U. S. A., 101, 13368, 10.1073/pnas.0403453101 · DOI · Paper page
- Raimondo, 2013, Differential protein profiling of renal cell carcinoma urinary exosomes, Mol. BioSyst., 9, 1220, 10.1039/c3mb25582d · DOI · Paper page
- Rodriguez-Suarez, 2014, Urine as a source for clinical proteome analysis: from discovery to clinical application, Biochim. Biophys. Acta, 1844, 884, 10.1016/j.bbapap.2013.06.016 · DOI
- Santucci, 2015, From hundreds to thousands: widening the normal human Urinome (1), J. Proteome, 112, 53, 10.1016/j.jprot.2014.07.021 · DOI
- Shao, 2015, Urinary protein biomarker database: a useful tool for biomarker discovery, Adv. Exp. Med. Biol., 845, 195, 10.1007/978-94-017-9523-4_19 · DOI
- Shao, 2011, A tool for biomarker discovery in the urinary proteome: a manually curated human and animal urine protein biomarker database, Mol. Cell. Proteomics, 10, 010975
- Shao, 2011, Applications of urinary proteomics in biomarker discovery, Sci. China Life Sci., 54, 409, 10.1007/s11427-011-4162-1 · DOI
- Stetson, 2006, Type I interferons in host defense, Immunity, 25, 373, 10.1016/j.immuni.2006.08.007 · DOI · Paper page
- Sun, 2009, Dynamic urinary proteomic analysis reveals stable proteins to be potential biomarkers, Proteomics Clin. Appl., 3, 370, 10.1002/prca.200800061 · DOI
- Sun, 2005, Human urine proteome analysis by three separation approaches, Proteomics, 5, 4994, 10.1002/pmic.200401334 · DOI
- Thompson, 2004, Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter, N. Engl. J. Med., 350, 2239, 10.1056/NEJMoa031918 · DOI · Paper page
- Uhlen, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 1260419, 10.1126/science.1260419 · DOI · Paper page
- Wang, 2006, Concanavalin A-captured glycoproteins in healthy human urine, Mol. Cell. Proteomics, 5, 560, 10.1074/mcp.D500013-MCP200 · DOI
- Wang, 2017, Exosomal proteins as prostate cancer biomarkers in urine: from mass spectrometry discovery to immunoassay-based validation, Eur. J. Pharm. Sci., 98, 80, 10.1016/j.ejps.2016.09.023 · DOI
- Wu, 2015, Physiological conditions can be reflected in human urine proteome and metabolome, Expert. Rev. Proteom., 12, 623, 10.1586/14789450.2015.1094380 · DOI · Paper page
- Yamamoto, 2008, Towards standard protocols and guidelines for urine proteomics: a report on the Human Kidney and Urine Proteome Project (HKUPP) symposium and workshop, 6 October 2007, Seoul, Korea and 1 November 2007, San Francisco, CA, USA, Proteomics, 8, 2156, 10.1002/pmic.200800138 · doi:10.1002/pmic.200800138
- Yu, 2014, Urine sample preparation in 96-well filter plates for quantitative clinical proteomics, Anal. Chem., 86, 5470, 10.1021/ac5008317 · DOI
- Zhang, 2007, MAPU: Max-Planck Unified database of organellar, cellular, tissue and body fluid proteomes, Nucleic Acids Res., 35, D771, 10.1093/nar/gkl784 · DOI
Cited by
Cancer metabolomic markers in urine: evidence, techniques and recommendations
Dinges, S. S., Hohm, A., Vandergrift, L. A., Nowak, J., Habbel, P., Kaltashov, I. A., & Cheng, L. L. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0185-3 · Cited by 161
Urine proteome of COVID-19 patients
(2020) · doi:10.1016/j.urine.2021.02.001 · Cited by 68
Urine proteomics identifies biomarkers for diabetic kidney disease at different stages
Fan, G., Gong, T., Lin, Y., Wang, J., Sun, L., Wei, H., Yang, X., Liu, Z., Li, X., Zhao, L., et al. (2021) · Clinical Proteomics · doi:10.1186/s12014-021-09338-6 · Cited by 38
Self-citationWang, Y., Sun, Y., Wang, Y., Jia, S., Qiao, Y., Zhou, Z., Shao, W., Zhang, X., Guo, J., Zhang, B., et al. (2023) · Alzheimer's Research & Therapy · doi:10.1186/s13195-023-01324-4 · Cited by 34
“We converted the iBAQ to the fraction of total (FOT) to normalize the differences in sample amounts [29], which was calculated by the iBAQ value of each protein divided by the total iBAQ of the sample, multiplied by 10 5 .”
MethodSelf-citation
Metadata
- Authors
- Leng, W., Ni, X., Sun, C., Lu, T., Malovannaya, A., Jung, S. Y., Huang, Y., Qiu, Y., Sun, G., Holt, M. V., Ding, C., Sun, W., Men, X., Shi, T., Zhu, W., Wang, Y., He, F., Zhen, B., Wang, G., & Qin, J.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 18
- Pages
- 300-310
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2601317354
- Cited by
- 44
- References
- 9
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes. https://app.cochat.ai/papers/10.1016/j.ebiom.2017.03.028
- The paper
- Leng, W., Ni, X., Sun, C., Lu, T., Malovannaya, A., Jung, S. Y., Huang, Y., Qiu, Y., Sun, G., Holt, M. V., Ding, C., Sun, W., Men, X., Shi, T., Zhu, W., Wang, Y., He, F., Zhen, B., Wang, G., & Qin, J. (2017). Proof-of-Concept Workflow for Establishing Reference Intervals of Human Urine Proteome for Monitoring Physiological and Pathological Changes. EBioMedicine. https://doi.org/10.1016/j.ebiom.2017.03.028
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.